Communiqués SynAct Pharma AB

Actions

SYNACT

SE0008241491

Produits pharmaceutiques

PEA

Marché Fermé - Nasdaq Stockholm 18:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
17,30 ^SEK	-0,92 %		-3,67 %	-23,45 %

16/09	Le resomelagon de Synact Pharma mis en avant par l'OMS dans la lutte contre la dengue	FW
16/09	SynAct Pharma identifie resomelagon comme l’un des six candidats médicaments contre la dengue disposant de preuves en faveur d’un développement clinique supplémentaire	CI

Communiqués

22/09	SynAct Pharma to participate in investor and partnering conferences	AQ
16/09	WHO identifies resomelagon as one of six dengue drug candidates with evidence supporting further clinical development	AQ
10/09	SynAct Pharma to Present at Investing in Life Science on September 22	AQ
08/09	SynAct Pharma : Bolagspresentation September 2026	PU
08/09	SynAct Pharma : Company presentation	PU
07/09	SynAct on phase III plans following new ADVANCE data	AQ
07/09	SynAct Pharma : Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development – FDA discussions on trial design planned for Q4 2026	PU
07/09	Further analysis of the Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development - FDA discussions on trial design planned for Q4 2026	AQ
03/09	SynAct Pharma : CEO and CSO sell shares	PU
03/09	SynAct Pharma's CEO and CSO sell shares	AQ
28/08	SynAct Pharma to present new resomelagon preclinical data on Phase 3-ready RA therapeutic candidate at the 17th World Congress of Inflammation 2026	AQ
20/08	SynAct Pharma (Q2 Review): Fenja Financing Backs the Post-ADVANCE Push	AQ
20/08	SynAct Pharma publishes Q2 2026 interim results	AQ
19/08	SynAct Pharma: Term Sheet Signed for Brazil	AQ
19/08	SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed	AQ
05/08	SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation	AQ
20/07	SynAct comments on the SEK 100 million facility	AQ
20/07	SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness	AQ
09/07	Resomelagon shows reduced inflammation and joint damage in osteoarthritis model	AQ
02/07	SynAct Pharma : Company presentation	PU
02/07	SynAct Pharma : Bolagspresentation	PU
29/06	BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study	AQ
16/06	SynAct Pharma: Updated Base Case after ADVANCE	AQ
15/06	SynAct Pharma (Interview): ADVANCE Topline Data	AQ
15/06	SynAct Pharma: 40mg Best Dose in ADVANCE	AQ